Abstract Although the pathogenesis underlying behavioral variant frontotemporal dementia (bvFTD) has yet to be fully understood, glutamatergic abnormalities have been hypothesized to play an important role. The aim of the present study was to determine the availability of the metabotropic glutamate receptor type 5 (mGluR5) using a novel positron emission tomography (PET) radiopharmaceutical with high selectivity for mGluR5 ([ 11 C]ABP688) in a sample of bvFTD patients. In addition, we sought to determine the overlap between availability of mGluR5 and neurodegeneration, as measured using [
Introduction
Behavioral variant frontotemporal dementia (bvFTD) is a progressive neurodegenerative syndrome characterized by change in personality, impaired social cognition, and executive dysfunction (Mendez et al. 2008; Swartz et al. 1997) . Approaching Alzheimer's disease (AD) as the leading cause of early-onset (before 65 years of age) dementia (Ratnavalli et al. 2002; Rosso et al. 2003) , bvFTD arises from a heterogeneous range of pathologies-referred to collectively as frontotemporal lobar degeneration (FTLD)-resulting in degenerative changes within frontal paralimbic, temporal and subcortical brain regions. In most cases, patients show either deposition of the microtubule associated protein tau (tau) or the TAR DNA-binding protein of 43 kDa (TDP) (Mackenzie et al. 2010) . A minority, however, show a defect in metabolism of the tumor-associated protein fused in sarcoma (FUS). The majority of FTLDs can therefore be classified into FTLD-tau, FTLD-TDP, or FTLD-FUS, with further subclassification based predominantly on inclusion morphology and lesion distribution (Mackenzie et al. 2010) .
Although the pathogenic mechanisms underlying bvFTD have yet to be fully elucidated, aberrant glutamatergic neurotransmission has been hypothesized to play a role. The primary excitatory neurotransmitter in the mammalian brain, glutamate acts via ionotropic and metabotropic receptors (Schaeffer and Duplantier 2010) . Whereas ionotropic receptors mediate fast excitatory neurotransmission, metabotropic glutamate receptors (mGluRs) play an important role in synaptic modulation via regulation of neuronal excitability, transmitter release, synaptic plasticity and glial function. In the case of bvFTD, FTLD has been found to accumulate preferentially within paralimbic and homotypical heteromodal brain regions, areas rich in excitatory glutamatergic pyramidal cells. Indeed, several autoradiographic and immunohistochemical studies in post-mortem bvFTD tissue have provided evidence supporting this hypothesis (Dalfo et al. 2005; Ferrer 1999; Procter et al. 1999) , highlighting reduced expression of the N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor. Importantly, activation of mGluR5 was shown to regulate glutamatergic neurotransmission via modulation of NMDA receptor functionality (Llansola and Felipo 2010; Niswender and Conn 2010; Perroy et al. 2008) . Moreover, mGluR5 signaling has been shown to be critically involved in the normal cognitive functioning of various neuronal populations (Schaeffer and Duplantier 2010) , including those within FTLD predilection sites (Ferraguti and Shigemoto 2006) .
Despite a strong in vitro evidence base, glutamatergic abnormalities in bvFTD have yet to be systematically characterized in vivo owing to the lack of suitable molecular probes. Using [
11 C]ABP688-a novel positron emission tomography (PET) radiopharmaceutical with high selectivity for mGluR5 (Ametamey et al. 2006 (Ametamey et al. , 2007 -we sought to measure mGluR5 availability and to determine the topographic overlap with neurodegeneration within frontotemporal and subcortical brain regions, as indexed using [
18 F]fluorodeoxyglucose ([ 18 F]FDG)-PET and voxelbased morphometry (VBM).
Methods

Subjects
Five patients meeting research criteria for probable bvFTD (Rascovsky et al. 2011) were recruited from the McGill Centre for Studies in Aging (MCSA) Alzheimer's Disease Research Unit. Exclusion criteria were (1) past or present use of memantine; (2) presence of other neurological diseases; (3) premorbid psychiatric disease or intellectual disability; (4) history of head injuries and loss of consciousness following head trauma; (5) current (within 1 month) use of psychoactive substances; (6) parkinsonism-as identified using the United Parkinson's Disease Rating Scale (Goetz et al. 2007 )-and (7) the presence of any major structural anomaly or signs of major vascular pathology on magnetic resonance imaging (MRI) evaluation (Roman et al. 1993) . All patients underwent neuropsychological assessment and behavioral testing. Global cognition was assessed using the Mini-Mental State Examination (MMSE) (Folstein et al. 1975) , with language and visuospatial function measured using the Wechsler Abbreviated Scale of Intelligence, second edition (McCrimmon and Smith 2013) . The Cogstate Research test battery was used to assess executive function, episodic memory, and social cognition (http://cogstate.com/tag/cog state-brief-battery/). The choice of measures included in the overall assessment battery took into consideration test availability in both English and French. Behavioral measures included the Neuropsychiatric Inventory (NPI) (Cummings et al. 1994) , and the Frontal Behavioral Inventory (FBI) (Kertesz et al. 1997 ). In addition, given that bvFTD and the frontal variant of AD are often difficult to differentiate on clinical grounds alone (Alladi et al. 2007) , all patients underwent carbon-11 Pittsburgh Compound B ([ 11 C]PiB) PET to rule out the presence of amyloid pathology. The diagnosis of bvFTD was determined during a multidisciplinary conference taking into consideration available medical, clinical, imaging, neuropsychological, and complementary laboratory information.
The bvFTD patients were matched by age and gender to a group of 10 cognitively normal (CN) controls, recruited via advertisements in a local newspaper. CN subjects were identified as individuals who (1) were independently functioning community dwellers; (2) did not have a personal or first degree relative history of psychiatric disorders; (3) had no cognitive complaints; (4) had a normal neurological and psychometric examination; (5) were not taking any psychoactive medications; (6) had no history of head trauma; (7) showed no signs of vascular pathology on MRI evaluation (Roman et al. 1993 ) and (8) had an MMSE score C29, an NPI score of 0, and an FBI score of 0.
Demographic and clinical data for all subjects are shown in Table 1 , with ratings of lobar atrophy (Kipps et al. 2007) and hypometabolism (Poljansky et al. 2011 ) for bvFTD patients shown in PET acquisition 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-11 Cmethyl-oxime ([ 11 C]ABP688) was synthesized as described previously (Elmenhorst et al. 2010) , with a radiochemical purity[99 %. The study was performed using a high-resolution research tomograph (HRRT) PET scanner (CTI/ Siemens, Knoxville, Tennessee), a brain-dedicated tomograph combining high spatial image resolution with high sensitivity. Prior to radiopharmaceutical administration, a 6-min transmission scan was acquired for scatter and attenuation correction using a [ , with emission data acquired in list-mode format, and binned into 26 time frames. For each and every time frame, sets of fully 3D sinograms were generated from the list-mode data (2,209 sinograms, span 9, with 256 radial bins and 288 azimuthal angle samples). A time-series of 26 3D images (frame duration: 6 9 30 s, 4 9 60 s, 8 9 120 s, 3 9 240 s, 5 9 300 s) were then reconstructed from these sinograms, each 3D image being composed of 256 9 256 9 207 cubic voxels (voxel side-length of 1.21875 mm), using an expectation maximization image reconstruction algorithm with an ordinary Poisson model of the acquired PET data. The reconstruction included full accounting for the normalization, attenuation, and timedependent scatter of random events. To reduce the partial volume effect, resolution modeling with point-spread function was implemented in the reconstruction (Comtat et al. 2008) . Subject head-motion correction was implemented using a data-driven motion estimation and correction method (Costes et al. 2009 transaxial slices simultaneously with an axial resolution of 5 mm full width at half maximum (FWHM) and an inplane resolution of 4.6 mm. Each collected slice had a thickness of 2.45 mm and a matrix size of 128 9 128 voxels. After correction for attenuation, scatter, decay and scanner-specific dead time, the PET data were reconstructed by filtered back-projection using a Hann filter (4.9 mm FWHM).
CN subjects had their acquisition conducted on the HRRT, with acquisition parameters identical to those for [ 11 C]ABP688, as described above. Images were reconstructed taking into consideration data acquired between 45 and 60 min only, with reconstruction matching that used for the HR? data. In order to compare data from the HRRT and HR? PET scanners, the resolution of the HRRT was matched to the partial volume effect of the HR?. To do so, an anisotropic Gaussian kernel of 5.7 9 5.7 9 6.7 mm FWHM was used, which was found to be the best match of scanner resolutions through an internal phantom study (unpublished data). In the case of [
18 F]FDG, two CN subjects were excluded owing to movement with one patient unable to return for the scan, reducing the sample size for [
18 F]FDG to 4 bvFTD and 8 CN.
Magnetic resonance imaging
For anatomical co-registration and identification of the volumes of interest (VOI), all subjects underwent a highresolution T-1 weighted MRI using a Siemens TRIO 3T scanner (Siemens Medical Solutions, Erlangen, Germany). Images were acquired in 3-D (voxel size = 1 mm 3 ; FOV = 256 9 256 mm; TR = 22 ms; TE = 9.2 ms; flip angle = 30°), with the scan performed on either on the same day or less than 2 weeks apart from the PET acquisitions, depending on the availability of the research slots.
Imaging analysis
values were obtained using the simplified reference tissue method (SRTM) (Gunn et al. 1997) , using the cerebellum as a reference region (Elmenhorst et al. 2009; Minuzzi et al. 2009 ). [
18 F]FDG-PET frames were summed and standardized uptake value ratio (SUV R ) maps calculated by normalizing the summed image to mean pontine activity for each subject. In order to correct for partial volume error (PVE), a modified version (Greve et al. 2014; Rousset et al. 2007 ) of the Muller-Gartner method (Muller-Gartner et al. 1992; Rousset et al. 1998 ) was implemented using the PVElab software package (https://nru.dk/downloads/soft ware/pveout/pveout.html) (Quarantelli et al. 2004) .
Following correction for field inhomogeneities (Sled and Evans 1998), native MRI volumes were nonlinearly resampled into standardized stereotaxic space, using the high-resolution ICBM template as reference (Fonov et al. 2009 ). Subsequently, normalized images were classified into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using an automatic algorithm (INSECT) (Zijdenbos and Evans 1998) . Voxel-based morphometry (VBM) (Ashburner and Friston 2000) was carried out on the structural segmented GM images nonlinearly resampled to the standard stereotaxic space after blurring with an isotropic Gaussian kernel of 10 mm FWHM. Finally, classified images were resampled to an anatomical template and automatically labeled using a probabilistic atlasbased approach (ANIMAL) (Collins et al. 1999; Collins and Evans 1997) . VOIs yielded by this procedure were subsequently applied to PET BP ND (cerebellum) and SUV R maps (pons).
Voxel-wise analysis maps of [ 11 C]ABP688 BP ND , [ 18 F]FDG SUV R , and VBM values were estimated using a basis functions approach (Gunn et al. 1997) , with PET images convolved using an isotropic Gaussian kernel of 6 mm FWHM. Parametric maps created in native space were then normalized into MNI space in order to allow for group comparisons. The resulting t-maps, calculated using RMINC (Lerch 2006) , show the areas with a significant difference in BP ND , SUV R , and relative concentration of GM between groups. Those areas were subsequently adjusted for a statistical cluster-wise threshold of p \ 0.05, and corrected for multiple comparisons using random field theory (Worsley et al. 1998 , and VBM-setting voxels less than the given threshold to 0 and voxels greater than the threshold to 1. Binary masks were then summed, with voxels having a value of 2 indicating overlap. In order to show areas exhibiting only reductions (e.g., in availability of mGluR5) binary masks were subtracted (e.g., [ 11 C]ABP688 BP ND -[ 18 F]FDG SUV R -VBM), with the range of values in the resulting volume restricted to lie between 0 and 1, removing negative values generated as a result of the subtraction. Finally, volumes were visualized and colorcoded using the software DISPLAY (http://www.bic.mni. mcgill.ca/software/Display/Display.html).
Results
Groups differed significantly in terms of MMSE, FBI and NPI (see Table 1 ). No differences were observed for age at scan, education, sex, or handedness. Since only two patients were capable of completing the entire neuropsychological assessment battery, quantitative assessment proved uninformative. Qualitative assessment based on the expert judgement of neuropsychologists (JP and CC) indicated clear deficits in executive and social cognitive measures in all bvFTD patients. Two patients displayed abnormal performance on measures of abstract and concrete language, with three showing deficits in visuospatial processing. While all patients showed moderate hypometabolism within frontotemporal regions, atrophy ranged from very mild to moderate (see Table 2 ).
Z score maps for regions with significantly reduced [ 11 C]ABP688 BP ND , hypometabolism and atrophy common to all patients-along with plots showing Z scores relative to controls are shown in Fig. 1 
, right lingual gyrus, and right cuneus. Additional declines were found in the right dorsolateral, right ventrolateral, and anterior prefrontal cortex, the right superior and middle temporal gyri, as well as in the temporal poles. No significant increases in [ 11 C]ABP688 binding were observed in bvFTD patients.
Significant hypometabolism was noted among bvFTD patients (116,742 mm 3 ) in extensive prefrontal areas, including the orbitofrontal (R [ L), ventromedial and dorsomedial prefrontal (L [ R), as well as the cingulate gyrus (L [ R) (corrected for multiple comparisons, p \ 0.05) (see Fig. 3 ). Metabolism was significantly reduced in the superior, middle, and inferior frontal gyri as well as in the precuneus and paracentral lobule (L [ R). Hypometabolism was also found in the bilateral insula (R [ L), uncus/amygdala, and parahippocampus (L [ R), as well as in subcortical structures, including the head of the caudatum and the left thalamus. There was also hypometabolism in the superior, middle, and inferior temporal gyri, temporal poles, and cerebellar tonsils.
Among bvFTD patients, grey matter loss (88,845 mm 3 ) was predominantly focused in the striatum-including the putamen (L [ R) and head of the caudate nucleus bilaterally (corrected for multiple comparisons, p \ 0.05; see Fig. 4 ). There was significant involvement of the thalamus and insula bilaterally, as well as the amygdala, and parahippocampus. Atrophy was also observed in the anterior cingulate (L [ R), precuneus (R [ L) gyrus rectus, orbitofrontal gyrus, as well as the right superior/middle temporal gyri, though to a lesser degree (see Table 3 ).
Overlap 
, left amygdala, right hippocampal formation, and the head of the caudate nucleus (R [ L) (14 179 mm 3 ; see Fig. 7 ). Though hypometabolism and atrophy were found in frontal, temporal, and subcortical brain regions, these declines were found to be inferior relative to those for [ 11 C]ABP688 BP ND in a wide range of areas, including the gyrus rectus, medial and lateral orbitofrontal cortex, ventromedial prefrontal cortex, left dorsomedial prefrontal cortex, paracentral lobule, frontal pole, left putamen, left insula, lingual gyrus, cuneus, temporal poles, right superior temporal gyrus, inferior and middle temporal gyri, and the right dorso-and ventrolateral prefrontal cortex.
Subtraction of binarized t-maps (
showed that decreased binding of Fig. 9 ). In addition, the orbitofrontal gyrus, the right middle temporal gyrus, right temporal operculum, left anterior insula, posterior insula bilaterally (R [ L), ventral amygdala (L [ R), left posterior inferior temporal gyrus, anterior cingulate gyrus (L [ R), the putamen (L [ R) and head of the caudate nucleus bilaterally, the thalamus as well as the posterior portion of the hippocampal formation, bilaterally, were found to be characterized only by GM reductions (VBM ; corrected for multiple comparisons, p \ 0.05). The dorso/ventromedial prefrontal cortex, cingulate gyrus, frontal gyri, paracentral lobule, precuneus, parahippocampus, thalamus, caudate and temporal lobes were characterized by leftward asymmetry. Hypometabolism was also noted with rightward asymmetry in the insula and orbitofrontal gyrus and in the cerebellar tonsils bilaterally
Discussion
The present findings represent the first in vivo report of decreased availability of mGluR5 in bvFTD. In line with recent studies showing reduced binding of [ 11 C]ABP688 in disorders characterized by glutamate excitotoxicity-such as major depressive disorder and temporal lobe epilepsy (Choi et al. 2014; Deschwanden et al. 2011 )-our findings may indicate altered glutamatergic neurotransmission in bvFTD, or conformational changes specific to the mGluR5 allosteric site. Further, we reproduced previous [
18 F]FDG and VBM findings in terms of both the topography of neurodegeneration and its partially asymmetric distribution (Diehl-Schmid et al. 2007; Hornberger et al. 2012; Jeong et al. 2005; Pan et al. 2012 ). In addition, we showed that the volume of decreased mGluR5 availability was inferior to that for hypometabolism and GM atrophy, and that the overlap between reduced [
11 C]ABP688 BP ND and hypometabolism was superior to that for GM atrophy. Moreover, we showed that declines in mGluR5 availability were unique to several isocortical, limbic, and paralimbic areas, possibly representing an early sign of pyramidal cell dysfunction. In this respect, the focality of [ 11 C]ABP688 BP ND reductions in the present study is striking given the widespread distribution of mGluR5. In addition, several frontotemporal areas showed hypometabolism and/or GM loss in the absence of reduced [
11 C]ABP688 binding. Taken together, these findings suggest a differential neuronal vulnerability to FTLD pathology in bvFTD-similar to that seen in other neurodegenerative diseases (Double et al. 2010 )-with reduced availability of mGluR5 possibly preceding neurodegeneration within select frontotemporal brain regions.
While at physiological concentrations glutamate is known to play a pivotal role in synaptic plasticity (Balschun et al. 2006; Huber et al. 2001 )-with any given function of a given cortical region likely to depend on glutamatergic neurotransmission at some level (Francis 2009 )-at high concentrations it has been shown to act as a neurotoxin, promoting neuronal injury and death in animal models (Rao et al. 2001; Rothstein 1996) and in neurodegenerative diseases, including AD (Francis 2003) . In the case of AD, accumulation of b-amyloid is thought to inhibit astroglial glutamate uptake, resulting in increased extracellular levels of glutamate, which, under chronic conditions, lead to cell death via sustained elevations in intracellular calcium (Harkany et al. 2000) . This excitotoxic scenario may explain decreased binding of (red) and VBM (blue) t-maps was found with leftward asymmetry in the anterior cingulate, ventromedial prefrontal cortex, thalamus, and head of the caudate nucleus. Rightward asymmetry was noted in the insula and orbitofrontal cortex [ 11 C]ABP688 in that continued high levels of glutamate may alter the availability of its transmembrane allosteric binding site (Ametamey et al. 2007 ) by altering mGluR5 conformational states (Cabello et al. 2009; Canela et al. 2009; Changeux and Edelstein 2005; Romano et al. 1996) . Indeed, affinity shifts in receptor-radioligand interactions have previously been described in the context of dopaminergic neurotransmission, where the affinity of a D2 PET radiopharmaceutical was altered following an amphetamine challenge (Narendran et al. 2004; Seneca et al. 2006; Wilson et al. 2005) .
Recently, an expanded hexanucleotide repeat in the chromosome 9 open reading frame 72 (C9ORF72) was identified as the most common cause of familial FTD and amyotrophic lateral sclerosis (ALS), with mutations associated with deposition of TDP-43 pathology (DeJesusHernandez et al. 2011; Renton et al. 2011) . While the pathogenic mechanism(s) by which this repeat expansion could cause disease remain unknown, induced pluripotent stem cell differentiated neurons from C9ORF72 ALS patients were shown to be highly susceptible to glutamate excitotoxicity (Donnelly et al. 2013) . Related work on primary cells from TDP-43 transgenic mice showed an increased vulnerability to the toxic effects of excess glutamate (Swarup et al. 2011) . Moreover, a recent study involving transgenic mice expressing the FTDP-17 mutation P301L in the human tau gene-resulting in the accumulation of hyperphosphorylated tau-showed a taudependent impairment of glutamate metabolism (Nilsen et al. 2013 ). These studies suggest that the pathogenicity of hyperphosphorylated tau and TDP-43-the molecular pathologies accounting for most cases of bvFTD )-may involve glutamatergic excitotoxicity.
Certain methodological aspects, however, limit interpretation of the present findings. In addition to this study's cross-sectional design and small sample size, the absence of histopathological data precludes conclusions about the homogeneity of the sample from the perspective of underlying molecular pathology. As such we were not able to address the possible interplay between different FTLD subtypes and possibly differing effects on mGluR5 availability. Moreover, potential limitations may accompany the use of VBM when applied to atrophic brains (Good et al. 2002) .
Despite these caveats, our findings shed light on the possible role of glutamate excitotoxicity in the pathogenesis of bvFTD and suggest that [ 11 C]ABP688 may prove a suitable non-invasive marker of glutamatergic neurotransmission in vivo. Larger prospective studies are required to ), including the bilateral insula, medial prefrontal cortex, left posterior paracentral lobule, left frontal operculum, anterior temporal poles, and bilateral cerebellar cortex. Leftward asymmetry was noted for the uncus/amygdalae, parahippocampus, and posterior cingulate/precuneus. Rightward asymmetry was noted for the orbitofrontal gyrus/gyrus rectus validate these findings, to establish the trajectory of reduced mGluR5 availability relative to other biomarkers of neurodegeneration, and to address the potential link between the dysregulation of glutamatergic neurotransmission and bvFTD symptomatology. 
